Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.
McComb S, Arbabi-Ghahroudi M, Hay KA, Keller BA, Faulkes S, Rutherford M, Nguyen T, Shepherd A, Wu C, Marcil A, Aubry A, Hussack G, Pinto DM, Ryan S, Raphael S, van Faassen H, Zafer A, Zhu Q, Maclean S, Chattopadhyay A, Gurnani K, Gilbert R, Gadoury C, Iqbal U, Fatehi D, Jezierski A, Huang J, Pon RA, Sigrist M, Holt RA, Nelson BH, Atkins H, Kekre N, Yung E, Webb J, Nielsen JS, Weeratna RD. McComb S, et al. Among authors: keller ba. Mol Ther Oncol. 2024 Feb 13;32(1):200775. doi: 10.1016/j.omton.2024.200775. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596311 Free PMC article.
Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.
Fergusson DA, Wesch NL, Leung GJ, MacNeil JL, Conic I, Presseau J, Cobey KD, Diallo JS, Auer R, Kimmelman J, Kekre N, El-Sayes N, Krishnan R, Keller BA, Ilkow C, Lalu MM. Fergusson DA, et al. Among authors: keller ba. Mol Ther Oncolytics. 2019 May 21;14:179-187. doi: 10.1016/j.omto.2019.05.004. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31276026 Free PMC article.
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.
Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC. Evgin L, et al. Among authors: keller ba. Mol Ther Oncolytics. 2016 Nov 16;3:16027. doi: 10.1038/mto.2016.27. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 27909702 Free PMC article.
Oncolytic viruses-immunotherapeutics on the rise.
Keller BA, Bell JC. Keller BA, et al. J Mol Med (Berl). 2016 Sep;94(9):979-91. doi: 10.1007/s00109-016-1453-9. Epub 2016 Aug 4. J Mol Med (Berl). 2016. PMID: 27492706 Review.
Oncolytic Viruses: The Best is Yet to Come.
Lemay CG, Keller BA, Edge RE, Abei M, Bell JC. Lemay CG, et al. Among authors: keller ba. Curr Cancer Drug Targets. 2018;18(2):109-123. doi: 10.2174/1568009617666170206111609. Curr Cancer Drug Targets. 2018. PMID: 28176648 Review.
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.
Wedge ME, Jennings VA, Crupi MJF, Poutou J, Jamieson T, Pelin A, Pugliese G, de Souza CT, Petryk J, Laight BJ, Boileau M, Taha Z, Alluqmani N, McKay HE, Pikor L, Khan ST, Azad T, Rezaei R, Austin B, He X, Mansfield D, Rose E, Brown EEF, Crawford N, Alkayyal A, Surendran A, Singaravelu R, Roy DG, Migneco G, McSweeney B, Cottee ML, Jacobus EJ, Keller BA, Yamaguchi TN, Boutros PC, Geoffrion M, Rayner KJ, Chatterjee A, Auer RC, Diallo JS, Gibbings D, tenOever BR, Melcher A, Bell JC, Ilkow CS. Wedge ME, et al. Among authors: keller ba. Nat Commun. 2022 Apr 7;13(1):1898. doi: 10.1038/s41467-022-29526-8. Nat Commun. 2022. PMID: 35393414 Free PMC article.
52 results